Serum d-serine levels are altered in early phases of Alzheimer’s disease: towards a precocious biomarker

d -Serine acts as a co-agonist of N -methyl- d -aspartate receptors (NMDAR) which appear overactivated in AD, while d -aspartate is a modulatory molecule acting on NMDAR as a second agonist. The aim of this work is to clarify whether the levels of these d -amino acids in serum are deregulated in AD,...

Full description

Saved in:
Bibliographic Details
Published inTranslational psychiatry Vol. 11; no. 1; pp. 77 - 8
Main Authors Piubelli, Luciano, Pollegioni, Loredano, Rabattoni, Valentina, Mauri, Marco, Princiotta Cariddi, Lucia, Versino, Maurizio, Sacchi, Silvia
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 26.01.2021
Nature Publishing Group
Subjects
631/378/340
692/53/2421
82/16
Alzheimer's disease
Behavioral Sciences
Biological Psychology
Biomarkers
Medicine
Medicine & Public Health
Neurosciences
Pharmacotherapy
Psychiatry
Online AccessGet full text

Cover

Abstract d -Serine acts as a co-agonist of N -methyl- d -aspartate receptors (NMDAR) which appear overactivated in AD, while d -aspartate is a modulatory molecule acting on NMDAR as a second agonist. The aim of this work is to clarify whether the levels of these d -amino acids in serum are deregulated in AD, with the final goal to identify novel and precocious biomarkers in AD. Serum levels of l - and d -enantiomers of serine and aspartate were determined by HPLC using a pre-column derivatization procedure and a selective enzymatic degradation. Experimental data obtained from age-matched healthy subjects (HS) and AD patients were statistically evaluated by considering age, gender, and disease progression, and compared. Minor changes were apparent in the serum l - and d -aspartate levels in AD patients compared to HS. A positive correlation for the d -serine level and age was apparent in the AD cohort. Notably, the serum d -serine level and the d -/total serine ratio significantly increased with the progression of the disease. Gender seems to have a minor effect on the levels of all analytes tested. This work proposes that the serum d -serine level and d -/total serine ratio values as novel and valuable biomarkers for the progression of AD: the latter parameter allows to discriminate CDR 2 and CDR 1 patients from healthy (CDR 0) individuals.
AbstractList Abstract d-Serine acts as a co-agonist of N-methyl-d-aspartate receptors (NMDAR) which appear overactivated in AD, while d-aspartate is a modulatory molecule acting on NMDAR as a second agonist. The aim of this work is to clarify whether the levels of these d-amino acids in serum are deregulated in AD, with the final goal to identify novel and precocious biomarkers in AD. Serum levels of l- and d-enantiomers of serine and aspartate were determined by HPLC using a pre-column derivatization procedure and a selective enzymatic degradation. Experimental data obtained from age-matched healthy subjects (HS) and AD patients were statistically evaluated by considering age, gender, and disease progression, and compared. Minor changes were apparent in the serum l- and d-aspartate levels in AD patients compared to HS. A positive correlation for the d-serine level and age was apparent in the AD cohort. Notably, the serum d-serine level and the d-/total serine ratio significantly increased with the progression of the disease. Gender seems to have a minor effect on the levels of all analytes tested. This work proposes that the serum d-serine level and d-/total serine ratio values as novel and valuable biomarkers for the progression of AD: the latter parameter allows to discriminate CDR 2 and CDR 1 patients from healthy (CDR 0) individuals.
D-Serine acts as a co-agonist of N-methyl-D-aspartate receptors (NMDAR) which appear overactivated in AD, while D-aspartate is a modulatory molecule acting on NMDAR as a second agonist. The aim of this work is to clarify whether the levels of these D-amino acids in serum are deregulated in AD, with the final goal to identify novel and precocious biomarkers in AD. Serum levels of L- and D-enantiomers of serine and aspartate were determined by HPLC using a pre-column derivatization procedure and a selective enzymatic degradation. Experimental data obtained from age-matched healthy subjects (HS) and AD patients were statistically evaluated by considering age, gender, and disease progression, and compared. Minor changes were apparent in the serum L- and D-aspartate levels in AD patients compared to HS. A positive correlation for the D-serine level and age was apparent in the AD cohort. Notably, the serum D-serine level and the D-/total serine ratio significantly increased with the progression of the disease. Gender seems to have a minor effect on the levels of all analytes tested. This work proposes that the serum D-serine level and D-/total serine ratio values as novel and valuable biomarkers for the progression of AD: the latter parameter allows to discriminate CDR 2 and CDR 1 patients from healthy (CDR 0) individuals.
d -Serine acts as a co-agonist of N -methyl- d -aspartate receptors (NMDAR) which appear overactivated in AD, while d -aspartate is a modulatory molecule acting on NMDAR as a second agonist. The aim of this work is to clarify whether the levels of these d -amino acids in serum are deregulated in AD, with the final goal to identify novel and precocious biomarkers in AD. Serum levels of l - and d -enantiomers of serine and aspartate were determined by HPLC using a pre-column derivatization procedure and a selective enzymatic degradation. Experimental data obtained from age-matched healthy subjects (HS) and AD patients were statistically evaluated by considering age, gender, and disease progression, and compared. Minor changes were apparent in the serum l - and d -aspartate levels in AD patients compared to HS. A positive correlation for the d -serine level and age was apparent in the AD cohort. Notably, the serum d -serine level and the d -/total serine ratio significantly increased with the progression of the disease. Gender seems to have a minor effect on the levels of all analytes tested. This work proposes that the serum d -serine level and d -/total serine ratio values as novel and valuable biomarkers for the progression of AD: the latter parameter allows to discriminate CDR 2 and CDR 1 patients from healthy (CDR 0) individuals.
D-Serine acts as a co-agonist of N-methyl-D-aspartate receptors (NMDAR) which appear overactivated in AD, while D-aspartate is a modulatory molecule acting on NMDAR as a second agonist. The aim of this work is to clarify whether the levels of these D-amino acids in serum are deregulated in AD, with the final goal to identify novel and precocious biomarkers in AD. Serum levels of L- and D-enantiomers of serine and aspartate were determined by HPLC using a pre-column derivatization procedure and a selective enzymatic degradation. Experimental data obtained from age-matched healthy subjects (HS) and AD patients were statistically evaluated by considering age, gender, and disease progression, and compared. Minor changes were apparent in the serum L- and D-aspartate levels in AD patients compared to HS. A positive correlation for the D-serine level and age was apparent in the AD cohort. Notably, the serum D-serine level and the D-/total serine ratio significantly increased with the progression of the disease. Gender seems to have a minor effect on the levels of all analytes tested. This work proposes that the serum D-serine level and D-/total serine ratio values as novel and valuable biomarkers for the progression of AD: the latter parameter allows to discriminate CDR 2 and CDR 1 patients from healthy (CDR 0) individuals.D-Serine acts as a co-agonist of N-methyl-D-aspartate receptors (NMDAR) which appear overactivated in AD, while D-aspartate is a modulatory molecule acting on NMDAR as a second agonist. The aim of this work is to clarify whether the levels of these D-amino acids in serum are deregulated in AD, with the final goal to identify novel and precocious biomarkers in AD. Serum levels of L- and D-enantiomers of serine and aspartate were determined by HPLC using a pre-column derivatization procedure and a selective enzymatic degradation. Experimental data obtained from age-matched healthy subjects (HS) and AD patients were statistically evaluated by considering age, gender, and disease progression, and compared. Minor changes were apparent in the serum L- and D-aspartate levels in AD patients compared to HS. A positive correlation for the D-serine level and age was apparent in the AD cohort. Notably, the serum D-serine level and the D-/total serine ratio significantly increased with the progression of the disease. Gender seems to have a minor effect on the levels of all analytes tested. This work proposes that the serum D-serine level and D-/total serine ratio values as novel and valuable biomarkers for the progression of AD: the latter parameter allows to discriminate CDR 2 and CDR 1 patients from healthy (CDR 0) individuals.
ArticleNumber 77
Author Princiotta Cariddi, Lucia
Versino, Maurizio
Piubelli, Luciano
Mauri, Marco
Sacchi, Silvia
Pollegioni, Loredano
Rabattoni, Valentina
Author_xml – sequence: 1
  givenname: Luciano
  orcidid: 0000-0003-0805-5121
  surname: Piubelli
  fullname: Piubelli, Luciano
  email: luciano.piubelli@uninsubria.it
  organization: Department of Biotechnology and Life Sciences, University of Insubria
– sequence: 2
  givenname: Loredano
  surname: Pollegioni
  fullname: Pollegioni, Loredano
  organization: Department of Biotechnology and Life Sciences, University of Insubria
– sequence: 3
  givenname: Valentina
  surname: Rabattoni
  fullname: Rabattoni, Valentina
  organization: Department of Biotechnology and Life Sciences, University of Insubria
– sequence: 4
  givenname: Marco
  surname: Mauri
  fullname: Mauri, Marco
  organization: Department of Biotechnology and Life Sciences, University of Insubria, Neurology Unit, Ospedale di Circolo and Fondazione Macchi, ASST Settelaghi
– sequence: 5
  givenname: Lucia
  surname: Princiotta Cariddi
  fullname: Princiotta Cariddi, Lucia
  organization: Center of Research in Medical Pharmacology, University of Insubria, Department of Medicine and Surgery, University of Insubria
– sequence: 6
  givenname: Maurizio
  surname: Versino
  fullname: Versino, Maurizio
  organization: Neurology Unit, Ospedale di Circolo and Fondazione Macchi, ASST Settelaghi, Department of Medicine and Surgery, University of Insubria
– sequence: 7
  givenname: Silvia
  orcidid: 0000-0002-2338-2561
  surname: Sacchi
  fullname: Sacchi, Silvia
  organization: Department of Biotechnology and Life Sciences, University of Insubria
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33500383$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1TAUtFARLaU_wAJZYsMm4EfiOCyQqopHpUosgLV14pzc64sTX-ykVVnxG_weX4Jv00LbRS1LtnxmxqNz5inZG8OIhDzn7DVnUr9JJZeNLpjgBeOCiUI-IgeCV7qQXOu9W_d9cpTShuVVlZrX_AnZl7JiWUQekM0XjPNAuyJhdCNSj-foE4WIFPyEETvqRooQ_SXdriFhoqGnx_7nGt2A8c-v34l2LmGuvKVTuIDYZTbdRrTBujAn2rowQPyO8Rl53INPeHR9HpJvH95_PflUnH3-eHpyfFZYxdRUCMFbCy1q1jQclEXgeQO0qued6pFJKZA3WGEJTd1Dg0qBxkplmihlKw_J6aLbBdiYbXT5-0sTwJmrhxBXBuLkrEfTK1FV0tpal7asVAsd6zgvVQ0db6VlWevdorWd2wE7i-MUwd8RvVsZ3dqswrmpdW4vE1ng1bVADD9mTJMZXLLoPYyYu2NEHomqFKubDH15D7oJcxxzq3YoppuSVTKjXtx29M_KzUgzQC8AG0NKEXtj3QSTCzuDzhvOzC5AZgmQyQEyVwEyO6q4R71Rf5AkF1LK4HGF8b_tB1h_AUvc2ds
CitedBy_id crossref_primary_10_3389_fnagi_2023_1211067
crossref_primary_10_1038_s41598_024_63164_y
crossref_primary_10_1016_j_nbd_2025_106849
crossref_primary_10_1111_cns_14704
crossref_primary_10_1088_2632_072X_ac5f8d
crossref_primary_10_3390_ijms252212410
crossref_primary_10_1016_j_celrep_2022_111271
crossref_primary_10_3390_biomedicines12040853
crossref_primary_10_12938_bmfh_2023_005
crossref_primary_10_2174_1567205019666220328123048
crossref_primary_10_1111_febs_16816
crossref_primary_10_3390_ijms222010917
crossref_primary_10_1111_febs_16953
crossref_primary_10_4155_bio_2023_0043
crossref_primary_10_3390_biom12060858
crossref_primary_10_1016_j_jbc_2024_105728
crossref_primary_10_3233_JAD_201217
crossref_primary_10_1007_s10571_023_01330_y
crossref_primary_10_1007_s11011_023_01289_1
crossref_primary_10_1007_s12033_022_00488_y
crossref_primary_10_1038_s41570_023_00476_z
crossref_primary_10_1167_iovs_66_1_36
crossref_primary_10_1007_s00726_020_02873_w
crossref_primary_10_2174_1567205019666220805105106
crossref_primary_10_1016_j_molmed_2023_09_001
crossref_primary_10_3390_cells11081367
crossref_primary_10_1016_j_ijbiomac_2024_129607
crossref_primary_10_1096_fj_202200394RRR
crossref_primary_10_1021_acsabm_1c00409
crossref_primary_10_3389_fmolb_2021_689719
crossref_primary_10_1007_s00018_020_03755_w
crossref_primary_10_1016_j_nbd_2024_106413
crossref_primary_10_1016_j_nbd_2024_106694
crossref_primary_10_3390_ijms24043274
crossref_primary_10_1038_s41398_024_02991_z
crossref_primary_10_3390_ijms22157887
crossref_primary_10_3389_fpsyt_2021_754032
crossref_primary_10_1016_j_pneurobio_2022_102331
crossref_primary_10_3390_ijms26052104
crossref_primary_10_1016_j_chroma_2021_462672
crossref_primary_10_3390_biom13050819
crossref_primary_10_3233_JAD_230142
crossref_primary_10_3390_ijms21134574
crossref_primary_10_1002_biof_1789
crossref_primary_10_1007_s11064_023_03873_4
Cites_doi 10.1038/tp.2015.52
10.1016/j.biopsych.2013.08.010
10.1016/0361-9230(91)90266-m
10.31887/DCNS.2009.11.2/cqiu
10.1038/s41537-017-0015-7
10.1111/j.1471-4159.2004.02548.x
10.14336/AD.2014.0423
10.1016/j.jalz.2011.03.005
10.1007/s00018-010-0307-9
10.1016/j.jalz.2011.03.004
10.1038/nature21029
10.1007/bf02815405
10.1073/pnas.94.5.2013
10.1016/j.expneurol.2019.02.014
10.1038/s41582-018-0079-7
10.2174/156720511796391917
10.1016/j.neurobiolaging.2010.03.008
10.1111/j.1476-5381.2012.02057.x
10.1016/j.neurobiolaging.2009.12.007
10.1002/gps.938
10.3233/JAD-160763
10.1016/j.neuropharm.2015.12.013
10.1016/j.pnpbp.2003.11.009
10.1007/bf01318865
10.1016/j.nbd.2019.104511
10.3389/fpsyt.2018.00014
10.1192/bjp.140.6.566
10.1038/s41591-018-0051-5
10.1007/s00726-012-1356-1
10.1016/j.schres.2012.09.014
10.1111/j.1474-9726.2012.00822.x
10.1074/jbc.M203946200
10.1016/j.neurobiolaging.2016.03.017
10.1111/apha.13257
10.1016/0361-9230(95)00087-u
10.1016/j.nbd.2003.09.016
10.1073/pnas.97.9.4926
10.1186/1742-2094-1-2
10.1002/gps.934
10.1073/pnas.1306832110
10.1523/JNEUROSCI.3881-15.2016
10.1016/j.pneurobio.2020.101801
10.1016/j.tibtech.2010.09.007
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41398-021-01202-3
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
PubMed
CrossRef
MEDLINE - Academic

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ - The Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2158-3188
EndPage 8
ExternalDocumentID oai_doaj_org_article_f62553cc784c456bad0d11467ad1b3c0
PMC7838302
33500383
10_1038_s41398_021_01202_3
Genre Journal Article
GrantInformation_xml – fundername: Fondo di Ateneo, University of Insubria
– fundername: ;
GroupedDBID ---
0R~
3V.
53G
5VS
7X7
88E
8FI
8FJ
AAJSJ
AAKDD
ABUWG
ACGFO
ACGFS
ACMJI
ACSMW
ADBBV
ADFRT
AENEX
AFKRA
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EMOBN
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
KQ8
LGEZI
LOTEE
M1P
M~E
NADUK
NAO
NXXTH
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
NPM
7XB
8FK
AARCD
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c606t-221bcabe80991a6cea1ea1aab6f1d6fe0332e19e5e4a97fa9e66a8e561bc243b3
IEDL.DBID 7X7
ISSN 2158-3188
IngestDate Wed Aug 27 01:29:24 EDT 2025
Thu Aug 21 14:13:14 EDT 2025
Sun Aug 24 04:09:24 EDT 2025
Wed Aug 13 05:12:44 EDT 2025
Thu Jan 02 22:58:50 EST 2025
Thu Apr 24 22:58:46 EDT 2025
Tue Jul 01 00:55:14 EDT 2025
Fri Feb 21 02:38:50 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-221bcabe80991a6cea1ea1aab6f1d6fe0332e19e5e4a97fa9e66a8e561bc243b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2338-2561
0000-0003-0805-5121
OpenAccessLink https://www.proquest.com/docview/2480894053?pq-origsite=%requestingapplication%
PMID 33500383
PQID 2480894053
PQPubID 2041978
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_f62553cc784c456bad0d11467ad1b3c0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7838302
proquest_miscellaneous_2481656079
proquest_journals_2480894053
pubmed_primary_33500383
crossref_citationtrail_10_1038_s41398_021_01202_3
crossref_primary_10_1038_s41398_021_01202_3
springer_journals_10_1038_s41398_021_01202_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-26
PublicationDateYYYYMMDD 2021-01-26
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-26
  day: 26
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
PublicationTitle Translational psychiatry
PublicationTitleAbbrev Transl Psychiatry
PublicationTitleAlternate Transl Psychiatry
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Lin (CR31) 2014
CR19
CR18
Nuzzo (CR37) 2017
CR17
CR39
Rudy, Hunsberger, Weitzner, Reed (CR13) 2015
CR16
CR38
CR15
CR14
CR36
CR35
CR12
CR34
CR11
CR33
CR10
CR32
Madeira (CR30) 2015
Qiu, Kivipelto, von Strauss (CR1) 2009; 11
Hynd, Scott, Dodd (CR40) 2004
CR2
CR4
Fisher (CR23) 1991
CR6
McKhann (CR3) 2011
CR5
CR8
CR29
CR28
CR9
CR27
CR26
CR25
CR24
CR22
CR44
CR21
CR43
CR20
CR42
Wenk (CR7) 2006; 3
CR41
1202_CR11
1202_CR33
1202_CR10
1202_CR32
1202_CR15
1202_CR14
1202_CR36
1202_CR35
1202_CR12
1202_CR34
MR Hynd (1202_CR40) 2004
C Madeira (1202_CR30) 2015
CH Lin (1202_CR31) 2014
GL Wenk (1202_CR7) 2006; 3
1202_CR19
1202_CR18
1202_CR17
1202_CR39
1202_CR16
1202_CR38
CC Rudy (1202_CR13) 2015
1202_CR22
1202_CR44
1202_CR2
1202_CR21
1202_CR43
1202_CR20
1202_CR42
1202_CR41
C Qiu (1202_CR1) 2009; 11
1202_CR26
1202_CR25
1202_CR24
1202_CR9
1202_CR8
1202_CR5
1202_CR6
1202_CR4
GH Fisher (1202_CR23) 1991
GM McKhann (1202_CR3) 2011
T Nuzzo (1202_CR37) 2017
1202_CR29
1202_CR28
1202_CR27
References_xml – ident: CR22
– ident: CR18
– ident: CR43
– ident: CR4
– ident: CR14
– ident: CR39
– ident: CR2
– ident: CR16
– ident: CR12
– ident: CR10
– ident: CR33
– ident: CR35
– ident: CR6
– ident: CR29
– ident: CR8
– ident: CR25
– ident: CR27
– year: 2015
  ident: CR30
  article-title: D-serine levels in Alzheimer’s disease: implications for novel biomarker development
  publication-title: Transl. Psychiatry
  doi: 10.1038/tp.2015.52
– ident: CR42
– year: 2014
  ident: CR31
  article-title: Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2013.08.010
– year: 1991
  ident: CR23
  article-title: Free D-aspartate and D-alanine in normal and Alzheimer brain
  publication-title: Brain Res. Bull.
  doi: 10.1016/0361-9230(91)90266-m
– ident: CR21
– volume: 11
  start-page: 111
  year: 2009
  end-page: 128
  ident: CR1
  article-title: Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention
  publication-title: Dialogues Clin. Neurosci.
  doi: 10.31887/DCNS.2009.11.2/cqiu
– ident: CR19
– ident: CR44
– year: 2017
  ident: CR37
  article-title: Decreased free D-aspartate levels are linked to enhanced D-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients
  publication-title: npj Schizophr.
  doi: 10.1038/s41537-017-0015-7
– year: 2004
  ident: CR40
  article-title: Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer’s disease
  publication-title: J. Neurochem.
  doi: 10.1111/j.1471-4159.2004.02548.x
– ident: CR15
– ident: CR38
– ident: CR17
– ident: CR11
– ident: CR9
– year: 2015
  ident: CR13
  article-title: The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer’s disease
  publication-title: Aging Dis.
  doi: 10.14336/AD.2014.0423
– ident: CR32
– ident: CR34
– ident: CR36
– ident: CR5
– year: 2011
  ident: CR3
  article-title: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.jalz.2011.03.005
– volume: 3
  start-page: 3
  year: 2006
  end-page: 7
  ident: CR7
  article-title: Neuropathologic changes in Alzheimer’s disease: potential targets for treatment
  publication-title: J. Clin. Psychiatry
– ident: CR28
– ident: CR41
– ident: CR26
– ident: CR24
– ident: CR20
– ident: 1202_CR26
  doi: 10.1007/s00018-010-0307-9
– ident: 1202_CR2
  doi: 10.1016/j.jalz.2011.03.004
– ident: 1202_CR20
  doi: 10.1038/nature21029
– ident: 1202_CR24
  doi: 10.1007/bf02815405
– ident: 1202_CR17
  doi: 10.1073/pnas.94.5.2013
– ident: 1202_CR22
  doi: 10.1016/j.expneurol.2019.02.014
– year: 2014
  ident: 1202_CR31
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2013.08.010
– ident: 1202_CR44
  doi: 10.1038/s41582-018-0079-7
– year: 2011
  ident: 1202_CR3
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.jalz.2011.03.005
– ident: 1202_CR29
  doi: 10.2174/156720511796391917
– ident: 1202_CR11
  doi: 10.1016/j.neurobiolaging.2010.03.008
– year: 2015
  ident: 1202_CR13
  publication-title: Aging Dis.
  doi: 10.14336/AD.2014.0423
– ident: 1202_CR5
  doi: 10.1111/j.1476-5381.2012.02057.x
– ident: 1202_CR18
  doi: 10.1016/j.neurobiolaging.2009.12.007
– year: 2004
  ident: 1202_CR40
  publication-title: J. Neurochem.
  doi: 10.1111/j.1471-4159.2004.02548.x
– ident: 1202_CR9
  doi: 10.1002/gps.938
– ident: 1202_CR8
  doi: 10.3233/JAD-160763
– ident: 1202_CR15
  doi: 10.1016/j.neuropharm.2015.12.013
– ident: 1202_CR33
  doi: 10.1016/j.pnpbp.2003.11.009
– ident: 1202_CR25
  doi: 10.1007/bf01318865
– ident: 1202_CR27
  doi: 10.1016/j.nbd.2019.104511
– ident: 1202_CR42
  doi: 10.3389/fpsyt.2018.00014
– volume: 3
  start-page: 3
  year: 2006
  ident: 1202_CR7
  publication-title: J. Clin. Psychiatry
– ident: 1202_CR36
  doi: 10.1192/bjp.140.6.566
– ident: 1202_CR21
  doi: 10.1038/s41591-018-0051-5
– ident: 1202_CR14
  doi: 10.1007/s00726-012-1356-1
– year: 2015
  ident: 1202_CR30
  publication-title: Transl. Psychiatry
  doi: 10.1038/tp.2015.52
– ident: 1202_CR39
  doi: 10.1016/j.schres.2012.09.014
– ident: 1202_CR43
  doi: 10.1111/j.1474-9726.2012.00822.x
– volume: 11
  start-page: 111
  year: 2009
  ident: 1202_CR1
  publication-title: Dialogues Clin. Neurosci.
  doi: 10.31887/DCNS.2009.11.2/cqiu
– year: 2017
  ident: 1202_CR37
  publication-title: npj Schizophr.
  doi: 10.1038/s41537-017-0015-7
– ident: 1202_CR38
  doi: 10.1074/jbc.M203946200
– ident: 1202_CR34
  doi: 10.1016/j.neurobiolaging.2016.03.017
– ident: 1202_CR35
  doi: 10.1111/apha.13257
– ident: 1202_CR32
  doi: 10.1016/0361-9230(95)00087-u
– ident: 1202_CR41
  doi: 10.1016/j.nbd.2003.09.016
– ident: 1202_CR16
  doi: 10.1073/pnas.97.9.4926
– year: 1991
  ident: 1202_CR23
  publication-title: Brain Res. Bull.
  doi: 10.1016/0361-9230(91)90266-m
– ident: 1202_CR28
  doi: 10.1186/1742-2094-1-2
– ident: 1202_CR6
  doi: 10.1002/gps.934
– ident: 1202_CR12
  doi: 10.1073/pnas.1306832110
– ident: 1202_CR19
  doi: 10.1523/JNEUROSCI.3881-15.2016
– ident: 1202_CR10
  doi: 10.1016/j.pneurobio.2020.101801
– ident: 1202_CR4
  doi: 10.1016/j.tibtech.2010.09.007
SSID ssj0000548171
Score 2.4634612
Snippet d -Serine acts as a co-agonist of N -methyl- d -aspartate receptors (NMDAR) which appear overactivated in AD, while d -aspartate is a modulatory molecule...
D-Serine acts as a co-agonist of N-methyl-D-aspartate receptors (NMDAR) which appear overactivated in AD, while D-aspartate is a modulatory molecule acting on...
d-Serine acts as a co-agonist of N-methyl-d-aspartate receptors (NMDAR) which appear overactivated in AD, while d-aspartate is a modulatory molecule acting on...
Abstract d-Serine acts as a co-agonist of N-methyl-d-aspartate receptors (NMDAR) which appear overactivated in AD, while d-aspartate is a modulatory molecule...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 77
SubjectTerms 631/378/340
692/53/2421
82/16
Alzheimer's disease
Behavioral Sciences
Biological Psychology
Biomarkers
Medicine
Medicine & Public Health
Neurosciences
Pharmacotherapy
Psychiatry
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojwDBRmJG0SNY8exuRVEVSHBiUq9WWN7ol20TVeb7YUTf6N_j1_C2MkuXZ4XpJwSOxnNIzOjmfnM2AvTKi8RbBmi0qXSXSyhiaGMELyMYJTtcoPsR31yqt6fNWfXjvpKPWEjPPDIuMOOAvRGhtAaFcjZe4hVTJO0LUThZcjZOvm8a8nUiOqtjGjFNCVTSXM40N86TZPVKXumjL-UO54oA_b_Lsr8tVnyp4ppdkTHd9jtKYLkRyPl--wG9nfZzQ9Tjfwe-0zmf3nOYznkyT6-SG1BA4cV8lwax8jnPccEbMyXM3JiA7_o-NHiywzn57j69vVq4FPZ5jVf565a2s2XKXUOqWOWp5H91NWzus9Oj999entSTicqlIESlXVZ18IH8GgoLhSgA4KgC8DrTkTdYSVljcJigwps24FFrcEgxVg-1Ep6-YDt9Rc9PmI80htEbCzFB1EJqCG2FjRCpdGCaULBxIa7Lkxw4-nUi4XLZW9p3CgRRxJxWSJOFuzlds9yBNv46-o3SWjblQkoO98g9XGT-rh_qU_BDjYid5P1Dq5WpjKWQln6xvPtY7K7VEyBHonVaU0GLmptwR6OGrKlRMomVVxpd7ujOzuk7j7p57OM7d0amRDZCvZqo2U_yPozKx7_D1Y8Ybfq0TzKWh-wvfXqEp9SxLX2z7JxfQegfSja
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKkRAXxJtAQUbiBhbxI47NrayoKiQ4Uam3aGI77KJtdpVsL5z4G_w9fglj54EWChJSTomdWJ4Z-5vMzGdCXphS1TKAZc4rzZRuPIPCO-bB1dKDUbZJCbIf9emZen9enB8QMdXCpKT9RGmZlukpO-x1j4ttLAYT0flFh53Ja-R6pG6PWr3Qi_m_CkIQw0s-1sfk0lzRdW8PSlT9V-HLP9Mkf4uVpi3o5Da5NWJHejyM9g45CO1dcuPDGB2_R76g4V9eUM_6VNNH1zEhqKfQBZqC4sHTVUtDpDSm2yVuXz3dNPR4_XUZVheh-_Hte0_HgM0bukv5tNibbqPT7GKuLI3F-jGfp7tPzk7efVqcsvEsBebQRdkxIXjtoA4GESEH7QJwvABq3XCvm5BLKQK3oQgKbNmADVqDCYiuaieUrOUDcthu2vCIUI9v4L6wiAy84iDAlxZ0gFwHC6ZwGeHT7FZuJBqP512sqxTwlqYaJFKhRKokkUpm5OXcZzvQbPyz9dsotLllpMhONzbd52pUmapBz66QzpVGOUSJNfjcxxLsEjyvpcszcjSJvBrttq-EMrmxCGLxG8_nx2hxMYwCbcCpjm0SZVFpM_Jw0JB5JFIWMdaKvcs93dkb6v6TdrVMrN6lkZGLLSOvJi37Nay_T8Xj_2v-hNwUgyEwoY_I4a67DE8RVe3qZ8mMfgKyHB4N
  priority: 102
  providerName: Springer Nature
Title Serum d-serine levels are altered in early phases of Alzheimer’s disease: towards a precocious biomarker
URI https://link.springer.com/article/10.1038/s41398-021-01202-3
https://www.ncbi.nlm.nih.gov/pubmed/33500383
https://www.proquest.com/docview/2480894053
https://www.proquest.com/docview/2481656079
https://pubmed.ncbi.nlm.nih.gov/PMC7838302
https://doaj.org/article/f62553cc784c456bad0d11467ad1b3c0
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fa9swEBdbC2MvY__nrQsa7G0TtSxbkvcy0tBSAitjWyFv5izJTUbqZHb6sqd9jX29fZKdFCUl-1MwGGzJyLqT9Dvd3U-EvNYqr4WDkhmbS5bLxjIorGEWTC0s6LxsQoDsmTw9z8eTYhI33PoYVrmZE8NEbRfG75EfZrlOdYnwQrxffmP-1CjvXY1HaNwm-566zId0qYna7rEgHNFc8Zgrkwp92OOc7XPKMm9Do93PxM56FGj7_4U1_w6Z_MNvGpajk_vkXsSRdLgW_ANyy7UPyZ0P0VP-iHzFSeDqklrWh_w-OvfBQT2FztHgIHeWzlrqPL0xXU5xKevpoqHD-fepm1267tePnz2Nzpt3dBVia7E2XXoD2vi4WeoT931sT_eYnJ8cfxmdsniuAjNorqxYlvHaQO00okMO0jjgeAHUsuFWNi4VInO8dIXLoVQNlE5K0A6RVm2yXNTiCdlrF617RqjFL3BblIgSbM4hA6tKkA5S6UrQhUkI3_RuZSLpuD_7Yl4F57fQ1VoiFUqkChKpRELebOss15QbN5Y-8kLblvR02eHBoruo4uirGrTyCmGM0rlBxFiDTa1Px1ZgeS1MmpCDjcirOIb76lrjEvJq-xpHn3epQOuwq32ZQF-kyoQ8XWvItiVCFN7virXVju7sNHX3TTubBoZvpYXnZUvI242WXTfr_13x_Oa_eEHuZmvFZ5k8IHur7sq9RES1qgdh2AzI_nA4_jzG-9Hx2cdP-HQkR4OwS_EbbLglXw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtMwGLZGJwE3iDOBAUaCK4gWH-I4SAhtsKljW4XQJu3Oc2yHFnVpaTohuOI1eAkeiifht5N0KofdTcpVYkeO_4O_P_8Joacy4wVzOo-N5SLmorSxTq2JrTYFs1ryvAwBsgPRP-TvjtKjFfSzy4XxYZWdTgyK2k6M_0e-TrlMZA7wgr2efo591yjvXe1aaDRsseu-fgGTrX618xbo-4zS7a2DN_247SoQGwDr85hSUhhdOAnYiGhhnCZwaV2IklhRuoQx6kjuUsd1npU6d0Jo6QBnFIZyVjB47yW0yhmYMj20urk1eP9h8VcHAJAkGWmzcxIm12s4JXwWG_VWOwX1w5ZOwNAo4F_o9u8gzT88teEA3L6OrrXIFW80rHYDrbjqJrq83_rmb6FPoHZOT7CN65BRiMc-HKnGeuZwcMk7i0cVdr6gMp4O4fCs8aTEG-NvQzc6cbNf33_UuHUXvcTzEM0Ls_HUm-zGR-piXyrARxPNbqPDC9nzO6hXTSp3D2ELbyA2zQGXWE401TbLtXA6ES7XMjURIt3uKtOWOffdNsYquNuZVA1FFFBEBYooFqHniznTpsjHuaM3PdEWI32B7nBjMvuoWnlXJdiVKTMmk9wARi20TaxPAM-0JQUzSYTWOpKrVmvU6ozHI_Rk8Rjk3TtxdOVgq_2YUDApyyN0t-GQxUoYS72nF2ZnS7yztNTlJ9VoGGqKZ5L5SnARetFx2dmy_r8V98__isfoSv9gf0_t7Qx2H6CrtBGCmIo11JvPTt1DwHPz4lErRBgdX7Tc_gZ8cmCE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLVKkSo2iHcDhRoJVhBNbCe2g4RQaRm1FCoWVJqdcWyHGTTNDMlUCFb8Br_C5_AlXDvJVMOju0pZJbbl-D587PtC6JEUacGczmNjUx6nvLSxzqyJrTYFs1qmeRkcZI_4_nH6epSN1tDPPhbGu1X2OjEoajsz_o58QFOZyBzgBRuUnVvEu73hi_nn2FeQ8pbWvpxGyyKH7usXOL41zw_2gNaPKR2-er-7H3cVBmIDwH0RU0oKowsnAScRzY3TBB6tC14Sy0uXMEYdyV3mUp2LUueOcy0dYI7C0JQVDMa9hC4LlhEvY2Iklvc7AIUkEaSL00mYHDSwX_h4NurP7xQUEVvZC0PJgH_h3L_dNf-w2YatcHgNXe0wLN5pme46WnPVDbTxtrPS30SfQAGdnmAbNyG2EE-9Y1KDde1wMM47iycVdj61Mp6PYRtt8KzEO9NvYzc5cfWv7z8a3BmOnuFF8OuF3njuD-_G--xinzTA-xXVt9Dxhaz4bbRezSq3ibCFEYjNckAoNiWaaityzZ1OuMu1zEyESL-6ynQJz33djakKhncmVUsRBRRRgSKKRejJss-8TfdxbuuXnmjLlj5Vd3gxqz-qTvJVCSfMjBkjZGoArRbaJtaHggttScFMEqGtnuSq0x-NOuP2CD1cfgbJ9-YcXTlYat8mpE4SeYTutByynAljmbf5Qm-xwjsrU139Uk3GIbu4kMznhIvQ057Lzqb1_6W4e_5fbKMNkFb15uDo8B66QlsZiCnfQuuL-tTdB2C3KB4ECcLow0WL7G_aCmNU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+d-serine+levels+are+altered+in+early+phases+of+Alzheimer%E2%80%99s+disease%3A+towards+a+precocious+biomarker&rft.jtitle=Translational+psychiatry&rft.au=Piubelli%2C+Luciano&rft.au=Pollegioni%2C+Loredano&rft.au=Rabattoni%2C+Valentina&rft.au=Mauri%2C+Marco&rft.date=2021-01-26&rft.issn=2158-3188&rft.eissn=2158-3188&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1038%2Fs41398-021-01202-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41398_021_01202_3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2158-3188&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2158-3188&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2158-3188&client=summon